SDZ 51641
SDZ 51641 is an orally active fatty acid oxidation inhibitor. By reducing fatty acid oxidation, SDZ 51641 deprives the gluconeogenesis process of required energy and cofactors, thereby lowering blood glucose levels in diabetic models. SDZ 51641 can be used in diabetes research.
For research use only. We do not sell to patients.
- CAS No.: 91456-99-4
- Formula: C14H20O2
- Molecular Weight:220.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
SDZ 51641 (700 µmol/kg; p.o.; once daily; for 28 days) reduces body weight and testicular weight, while increases liver weight, in normal Sprague Dawley rats compared with the control group[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague‑Dawley rats treated STZ[1]
-
Dosage:70 µmol/kg
-
Administration:p.o.; daily; 11 days
-
Result:Inhibited hepatic fatty acid oxidation, decreased β‑hydroxybutyrate levels, reduced blood glucose production, and lowered serum glucose levels, while avoiding toxic effects on peripheral tissues such as the testes.
Chemical Information
-
CAS No. 91456-99-4
-
Molecular Weight 220.31
-
Formula C14H20O2
-
SMILES
CC(C=C1)=CC=C1C2(C(C)(C)C)OCCO2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- SDZ 51641
- 91456-99-4
- SDZ51641
- SDZ-51641
- Drug Intermediate
- long-chain acyl dehydrogenase
- fatty acid oxidation
- STZ-induced diabetic rats
- gluconeogenesis
- Sprague Dawley rats
- testicular toxicity
- carnitine palmitoyl transferase 2
- intramitochondrial CoA
- acetyl-CoA
- non-insulin-dependent diabetes mellitus
- Inhibitor
- inhibitor
- inhibit